- Boryung has signed a CDMO agreement with Cheplapharm to manufacture and globally supply Zyprexa tablets to 46 countries.
- This is Boryung’s first global oral formulation CDMO contract and follows EU-GMP certification of its Yesan campus.
Boryung Corp. has signed a global contract development and manufacturing organisation (CDMO) agreement with Germany-based Cheplapharm for the production and supply of Zyprexa (olanzapine) tablets, the company announced on 17 July. Under the contract, Boryung will supply the schizophrenia treatment to 46 countries, including those in Europe and North America, starting from the fourth quarter of 2025.
This marks Boryung’s first global CDMO contract for an oral formulation, building on its existing injectable manufacturing capabilities. All Zyprexa tablets will be manufactured at the company’s Yesan campus, which received EU-GMP certification for its anticancer injectable line in 2023. The oral formulation line is currently undergoing certification from the EU, US FDA, and Brazil’s ANVISA to support broader international access.
A Boryung official noted that the contract was enabled by “technical trust” in the Yesan facility, which meets international quality standards. “It was crucial that Cheplapharm recognized both the stability and production capacity of the high-quality oral formulation production facility equipped with the latest equipment,” the official said.
Cheplapharm acquired the global rights (excluding Korea) to Zyprexa from Eli Lilly in 2023 and supplies medicines to over 145 countries. Boryung had previously obtained the Korean rights to the drug in 2021 and began in-house production following tech transfer and bioequivalence verification.
According to Boryung’s Chief Strategy Officer, Kim Sung-jin, the contract represents a key milestone in the company’s global ambitions. “We will continue to create opportunities for global expansion of our CDMO business, including expanding various collaborations with Cheplapharm, based on this cooperation,” he stated.
